The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins
Open accessAbstract
The mechanism by which the drug rapamycin inhibits the mechanistic target of rapamycin (mTOR) is of intense interest because of its likely relevance in cancer biology, aging, and other age-related diseases. While rapamycin acutely and directly inhibits mTORC1, only chronic administration of rapamycin can inhibit mTORC2 in some, but not all, cell lines or tissues. The mechanism leading to cell specificity of mTORC2 inhibition by rapamycin is not understood and is especially important because many of the negative metabolic side effects of rapamycin, reported in mouse studies and human clinical trials, have been attributed recently to mTORC2 inhibition. Here, we identify the expression level of different FK506-binding proteins (FKBPs), primarily FKBP12 and FKBP51, as the key determinants for rapamycin-mediated inhibition of mTORC2. In support, enforced reduction of FKBP12 completely converts a cell line that is sensitive to mTORC2 inhibition to an insensitive cell line, and increased expression can enhance mTORC2 inhibition. Further reduction of FKBP12 in cell lines with already low FKBP12 levels completely blocks mTORC1 inhibition by rapamycin, indicating that relative FKBP12 levels are critical for both mTORC1 and mTORC2 inhibition, but at different levels. In contrast, reduction of FKBP51 renders cells more sensitive to mTORC2 inhibition. Our findings reveal that the expression of FKBP12 and FKBP51 is the rate limiting factor that determines the responsiveness of a cell line or tissue to rapamycin. These findings have implications for treating specific diseases, including neurodegeneration and cancer, as well as targeting aging in general.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 3×
“…a nutrient responsive kinase that integrates signals from growth factors, amino acids, energy, and stress to regulate cell growth and proliferation (Zoncu et al., 2011; Dibble & Manning, 2013). mTOR is the catalytic subunit of two distinct complexes, mTORC1 and mTORC2; the former regulates protein…”
BackgroundRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120 · cited 2×
“Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins Katherine H. Schreiber, Denise Ortiz, Emmeline C. Academia, Arieanna C. Anies, Chen-Yu Liao and Brian K. Kennedy The Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA”
BackgroundInfluence of TOR kinase on lifespan in C. elegans
Vellai, T., Takacs-Vellai, K., Zhang, Y., Kovacs, A. L., Orosz, L., & Müller, F. (2003) · Nature · doi:10.1038/426620a · Cited by 1,057
Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A. (2010) · Diabetes · doi:10.2337/db09-1324 · Cited by 456
Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427
Research works printed but not linked: 30
- 10.1006/bbrc.1997.6307 · DOI
- 10.1016/j.cmet.2009.11.010 · DOI · Paper page
- 10.1126/scisignal.2000559 · DOI · Paper page
- 10.1038/ncb2763 · DOI · Paper page
- 10.1128/MCB.00735-09 · DOI · Paper page
- 10.1126/science.1059497 · DOI · Paper page
- 10.1111/acel.12109 · DOI · Paper page
- 10.2337/db07-0922 · DOI · Paper page
- 10.1111/j.1474-9726.2006.00267.x · DOI · Paper page
- 10.1083/jcb.200403069 · DOI · Paper page
- 10.1126/science.1715094 · DOI · Paper page
- 10.1128/MCB.00601-09 · DOI · Paper page
- 10.1016/j.mad.2004.10.007 · DOI · Paper page
- 10.1126/science.1115535 · DOI · Paper page
- 10.1126/sageke.2004.36.pe34 · DOI
- 10.1016/j.cub.2004.03.059 · DOI · Paper page
- 10.1016/j.cmet.2010.05.001 · DOI · Paper page
- 10.1016/S0092-8674(02)00808-5 · DOI · Paper page
- 10.1124/mol.107.043398 · DOI · Paper page
- 10.1016/j.cell.2012.03.017 · DOI · Paper page
- Liang J, 1999, Refined structure of the FKBP12‐rapamycin‐FRB ternary complex at 2.2 A resolution, Acta Crystallogr. D Biol. Crystallogr., 55, 736, 10.1107/S0907444998014747 · DOI · Paper page
- 10.1128/MCB.00678-12 · DOI · Paper page
- 10.1098/rstb.2010.0198 · DOI
- Neshat MS, 2001, Enhanced sensitivity of PTEN‐deficient tumors to inhibition of FRAP/mTOR, Proc. Natl Acad. Sci. USA, 98, 10314, 10.1073/pnas.171076798 · DOI · Paper page
- 10.1371/journal.pgen.1003708 · DOI
- 10.1111/j.1474-9726.2006.00266.x · DOI · Paper page
- 10.1101/gad.1381406 · DOI · Paper page
- 10.1016/j.molcel.2006.03.029 · DOI · Paper page
- 10.1111/j.1600-6143.2008.02537.x · DOI
- 10.1016/j.bbagen.2009.06.007 · DOI · Paper page
Cited by
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876
“Quantification of p-S6K/S6K and p-AKT S473 /AKT ratios was performed as described 46, 47 .”
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., & Kroemer, G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.22 · Cited by 842
Molecular mechanisms of dietary restriction promoting health and longevity
Green, C. L., Lamming, D. W., & Fontana, L. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00411-4 · Cited by 714
The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging
Kennedy, B. K., & Lamming, D. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.009 · Cited by 544
Self-citationThe quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Self-citationmTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
mTOR as a central regulator of lifespan and aging
Papadopoli, D., Boulay, K., Kazak, L., Pollak, M., Mallette, F., Topisirovic, I., & Hulea, L. (2019) · F1000Research · doi:10.12688/f1000research.17196.1 · Cited by 440
Jiang, G.-M., Tan, Y., Wang, H., Peng, L., Chen, H.-T., Meng, X.-J., Li, L.-L., Liu, Y., Li, W.-F., & Shan, H. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0944-z · Cited by 365
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Arriola Apelo, S. I., Neuman, J. C., Baar, E. L., Syed, F. A., Cummings, N. E., Brar, H. K., Pumper, C. P., Kimple, M. E., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12405 · Cited by 182
“The effect of chronic rapamycin treatment on AKT S473 phosphorylation can be difficult to observe and is time sensitive (Schreiber et al., 2015), and so we may have only observed this effect in skeletal muscle due to the time point utilized.”
BackgroundSex‐ and tissue‐specific changes in mTOR signaling with age in C57 BL /6J mice
Baar, E. L., Carbajal, K. A., Ong, I. M., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12425 · Cited by 177
A novel rapamycin analog is highly selective for mTORC1 in vivo
Schreiber, K. H., Arriola Apelo, S. I., Yu, D., Brinkman, J. A., Velarde, M. C., Syed, F. A., Liao, C.-Y., Baar, E. L., Carbajal, K. A., Sherman, D. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11174-0 · Cited by 177
Self-citationYu, D., Tomasiewicz, J. L., Yang, S. E., Miller, B. R., Wakai, M. H., Sherman, D. S., Cummings, N. E., Baar, E. L., Brinkman, J. A., Syed, F. A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.084 · Cited by 98
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
Walters, H. E., & Cox, L. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082325 · Cited by 85
Lamming, D. W., Cummings, N. E., Rastelli, A. L., Gao, F., Cava, E., Bertozzi, B., Spelta, F., Pili, R., & Fontana, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5180 · Cited by 69
“We and others have demonstrated that chronic treatment of mice with rapamycin results in the disruption of both mTOR complexes [18, 19].”
Dominick, G., Bowman, J., Li, X., Miller, R. A., & Garcia, G. G. (2017) · Aging Cell · doi:10.1111/acel.12525 · Cited by 62
Hypothalamic mTORC2 is essential for metabolic health and longevity
Chellappa, K., Brinkman, J. A., Mukherjee, S., Morrison, M., Alotaibi, M. I., Carbajal, K. A., Alhadeff, A. L., Perron, I. J., Yao, R., Purdy, C. S., et al. (2019) · Aging Cell · doi:10.1111/acel.13014 · Cited by 62
Pharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles
Deng, Z., Dong, Y., Zhou, X., Lu, J.-H., & Yue, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.009 · Cited by 58
Arriola Apelo, S. I., Lin, A., Brinkman, J. A., Meyer, E., Morrison, M., Tomasiewicz, J. L., Pumper, C. P., Baar, E. L., Richardson, N. E., Alotaibi, M., et al. (2020) · eLife · doi:10.7554/elife.56177 · Cited by 34
Mechanosensitive mTORC1 signaling maintains lymphatic valves
Saygili Demir, C., Sabine, A., Gong, M., Dormond, O., & Petrova, T. V. (2023) · Journal of Cell Biology · doi:10.1083/jcb.202207049 · Cited by 24
Sharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Metadata
- Authors
- Schreiber, K. H., Ortiz, D., Academia, E. C., Anies, A. C., Liao, C., & Kennedy, B. K.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2015-02-04
- Volume
- 14
- Issue
- 2
- Pages
- 265-273
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W1999935726
- Cited by
- 177
- References
- 7
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Funders
- National Institutes of Health (R01AG033373, F32GM103149)
- Ellison Medical Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.